A new blood test could prevent men with prostate cancer after months of strenuous chemotherapy

A revolutionary new blood test promises to preserve men with prostate cancer from months of strenuous chemotherapy

A revolutionary new blood test promises to preserve men with prostate cancer from months of strenuous chemotherapy.

Scientists at the Cancer Research Institute in London have used the new test to analyze tumors in greater detail than ever by filtering cancer cells from the blood.

The test allows them to detect when prostate cancer is beginning to evolve to become resistant to chemotherapy.

This allows them to move quickly to other treatments, such as hormonal medications or immunotherapy.

At the moment, most chemotherapy only stops when the symptoms of cancer begin to worsen, a sign that the tumor has evolved and is beginning to spread again. But this means that men can suffer months of debilitating treatment that does not really work.

A revolutionary new blood test promises to preserve men with prostate cancer from months of strenuous chemotherapy

A revolutionary new blood test promises to preserve men with prostate cancer from months of strenuous chemotherapy

The Daily Mail is campaigning for urgent improvements in the treatment and diagnosis of prostate cancer, which are lagging behind others such as breast cancer.

Some 10,000 men with prostate cancer receive chemotherapy every year, from the 47,000 men diagnosed in Britain annually.

The new test is one of the first liquid biopsies that experts believe will revolutionize the treatment of cancer. The leader of the study, Professor Johann de Bono, said: "Using the new blood test before, during and after treatment will allow us to closely observe how a person's cancer evolves in response to drugs.

& # 39;[It] it could allow us to detect treatment failure at an earlier stage, so we can change people with advanced prostate cancer to treatments that are more likely to work. "

Over time, this technology could allow doctors to focus precisely on cancers according to their genetic make-up, monitor tumors closely as they evolve, and change drugs if the cancer becomes resistant to some treatment.

Experts believe that patients can skip unnecessary chemotherapy, the NHS will save hundreds of millions of pounds and save thousands of lives as the drugs become more accurate.

The new test captures tumor cells in the blood, offering a detailed view of their genetic makeup.

Until now, this degree of knowledge has only been possible when taking biopsy samples, a painful procedure. Because they are invasive, biopsies can not be done often, which means that if the cancer mutates, it can take months to notice.

Scientists at the London Cancer Research Institute have used the new test to analyze tumors in greater detail than ever by filtering cancer cells from the blood

Scientists at the London Cancer Research Institute have used the new test to analyze tumors in greater detail than ever by filtering cancer cells from the blood

Scientists at the London Cancer Research Institute have used the new test to analyze tumors in greater detail than ever by filtering cancer cells from the blood

The new blood test, in comparison, takes 90 minutes, which means that doctors can repeat it every few days and can tell instantly what the cancer is doing.

Doctors have had difficulty doing this before, since solid tumors, such as prostate cancer, are relatively stable, so they do not shed many cells into the bloodstream.

The team today published the results of the first use of the test, in 14 men with advanced prostate cancer at the Royal Marsden NHS cancer hospital.

The findings, in the medical journal Clinical Cancer Research, showed that about 12,500 cancer cells were removed per sample, compared to 167 of the usual methods.

The team discovered that they could even use these cells to start growing "minitumorites," allowing them to run tests to see what medications work. Bono's teacher is embarking on a larger test with 1,000 men. He said: "This could stop chemotherapy probably two courses before."

(function() {
var _fbq = window._fbq || (window._fbq = []);
if (!_fbq.loaded) {
var fbds = document.createElement(‘script’);
fbds.async = true;
fbds.src = “http://connect.facebook.net/en_US/fbds.js”;
var s = document.getElementsByTagName(‘script’)[0];
s.parentNode.insertBefore(fbds, s);
_fbq.loaded = true;
}
_fbq.push([‘addPixelId’, ‘1401367413466420’]);
})();
window._fbq = window._fbq || [];
window._fbq.push([“track”, “PixelInitialized”, {}]);
.